Toxicity of the topoisomerase II inhibitors.
Topoisomerase II inhibitors represent a broad class of antineoplastic agents with a wide spectrum of activity against malignancies. Topoisomerase II inhibitors include the anthracyclines, mitoxantrone and epipodophyllotoxins. Short-term toxicity includes myelosuppression and gastrointestinal toxicity. Long-term survivors are at risk of cardiac toxicity and secondary leukaemia. This article discusses these toxicities in detail, including administration of these agents to patients with hepatic and/or renal insufficiency, and the need for dose adjustments in selected patient populations.
Seiter
Karen
K
New York Medical College, Room 250 Munger Pavilion, Valhalla, New York 10595, USA. Karen_Seiter@nymc.edu
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003630:Daunorubicin / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D015251:Epirubicin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects; D007938:Leukemia / Q000139:chemically induced; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects; D052016:Mucositis / Q000139:chemically induced; D011034:Podophyllotoxin / Q000009:adverse effects; D013713:Teniposide / Q000009:adverse effects; D059005:Topoisomerase II Inhibitors; D014652:Vascular Diseases / Q000139:chemically induced
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D015251:Epirubicin; D005047:Etoposide; D004317:Doxorubicin; D013713:Teniposide; D008942:Mitoxantrone; D011034:Podophyllotoxin; D015255:Idarubicin; D003630:Daunorubicin